Association between CHADS2 Score and the Preventive Effect of Statin Therapy on New-Onset Atrial Fibrillation in Patients with Acute Myocardial Infarction

Shao-Sung Huang1,2,4, Wan-Leong Chan1,2,4, Hsin-Bang Leu1,2,4, Po-Hsun Huang1,4, Jaw-Wen Chen1,3,5, Shing-Jong Lin1,3,4*

1 Division of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 2 Healthcare and Management Center, Taipei Veterans General Hospital, Taipei, Taiwan, 3 Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan, 4 Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan, 5 Institute and Department of Pharmacology, National Yang-Ming University, Taipei, Taiwan

Abstract

Objectives: New-onset atrial fibrillation (AF) commonly occurs in patients with acute myocardial infarction (AMI). Data regarding the value of the CHADS2 score in patients hospitalized for AMI is limited. This study aimed to determine whether the CHADS2 score is associated with new-onset AF and if it can help identify the patients who will benefit most from statin use for the prevention of arrhythmia after AMI.

Methods: A total of 724 consecutive AMI patients were enrolled in this study. The patients were divided into 3 groups according to their CHADS2 scores: group 1, score 0; group 2, score 1–2; and group 3, score 3–6. The study endpoint was an episode of new-onset AF that lasted more than 30 seconds during hospitalization at the coronary care unit.

Results: Seventy-eight (10.8%) patients developed new-onset AF, and 273 (37.7%) were on a statin upon admission. The incidence of new-onset AF increased significantly from 5.8% in group 1 to 11.3% in group 2 and 14.3% in group 3 (χ² for linear trend, P = 0.017). Statin use (odds ratio [OR], 0.22; 95% CI, 0.06–0.85) and CHADS2 score (OR, 1.53; 95% CI, 1.02–2.28) were independent predictors of new-onset AF in AMI patients. Patients with CHADS2 score ≤2 had significantly reduced C-reactive protein level and lower risk of developing new-onset AF if they were taking statins (P < 0.05). Multivariate logistic regression analysis demonstrated the benefit of statin use for preventing new-onset AF in patients with CHADS2 scores ≤2 (OR, 0.34; 95% CI, 0.14–0.81).

Conclusions: The CHADS2 score is a convenient scoring system for predicting the incidence of new-onset AF and may help in identifying the patients who will benefit most from statin use for the prevention of arrhythmia after AMI.

Introduction

Preexisting or new-onset atrial fibrillation (AF) commonly occurs in patients with acute coronary syndrome (ACS) [1,2] and is associated with complications. Using data from patients with ACS, who were enrolled in the Global Registry of Acute Coronary Events, Mehta et al. found that preexisting and new-onset AF are associated with increased hospital morbidity and mortality as compared to ACS patients without any AF. However, only new-onset AF is an independent predictor of inhospital adverse events in patients with ACS [3]. Moreover, AF is associated with a greater 30-day mortality (29.3% vs. 19.1%) and 1-year mortality (48.3% vs. 32.7%) in patients with acute myocardial infarction (AMI) [2]. AF is more commonly associated with AMI in older patients and in those with higher Killip class or left ventricular dysfunction [4]. Accumulating evidence indicates that apart from triggers, AF development and perpetuation depends on the electrical and structural remodeling of the atria [5]. Thus, many studies on pharmacological therapies have shifted to non-channel blocking drugs with pleiotropic properties that have the potential to alter the underlying atrial substrate without concomitant pro-arrhythmic effects [6,7].

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (i.e., statins) are highly effective and widely used lipid-lowering agents. The beneficial effects of aggressive statin therapy in ACS as well as analyses of indexes of inflammation, oxidation, and thrombosis support the existence of relevant pleiotropic...
Effects [8,9]. Although observational studies support the protective role of statins against AF in ACS patients [10], data recommending the use of statins to prevent AF are insufficient [11]. The CHADS2 score (i.e., congestive heart failure, hypertension, age >75 years, diabetes, and previous stroke/transient ischemic attack) is used for embolic risk stratification and guidance in the management of patients with AF [12]. Recent studies demonstrate that a higher CHADS2 score is associated with a risk of recurrence after catheter ablation of AF [13,14]. However, no published studies have investigated the role of the CHADS2 score in the prediction of new-onset AF in patients presenting with AMI. Therefore, this study aimed to determine whether the CHADS2 score is associated with new-onset AF and if it can help identify the AMI patients who will benefit most from statin use for the prevention of arrhythmia.

Methods

Study Population

This was a retrospective study of consecutive patients with AMI admitted to a coronary care unit (CCU) between May 2002 and December 2005. AMI was defined as detection of elevated troponin I level ≥0.1 ng/mL, accompanied by either typical chest pain for >30 min and/or electrocardiographic changes (including ischemic ST-segment depression, ST-segment elevation, or pathologic Q waves). A transthoracic echocardiogram was recorded in each patient. Before enrollment, each patient’s chart was reviewed in detail to gather data on medications, coronary risk factors, previous cardiovascular events, and other systemic diseases. Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or antihypertensive treatment. Diabetes mellitus was defined as fasting plasma glucose levels ≥126 mg/dL or the use of hypoglycemic agents. Serum creatinine levels >2 mg/dL was classified as renal insufficiency. Killip class I was defined as absence of heart failure, class II as presence of raes and/or jugular venous distension, class III as presence of pulmonary edema and class IV as cardiogenic shock. Patients with hyperthyroidism, rheumatic valvular disease, and chronic AF were excluded. To reduce patient selection bias, there was no age limit or other specific exclusion criteria. Among the 747 screened patients, 23 were excluded due to rheumatic valvular disease (n = 2) or chronic AF (n = 21). This study was approved by the research ethics committee of Taipei Veterans General Hospital. The informed consent requirement was waived by the Institutional Review Board because researchers only accessed retrospectively a de-identified database for analysis purposes.

Risk score calculation

The CHADS2 score was calculated for each patient by assigning 1 point each for age >75 years, hypertension, diabetes mellitus, and previous heart failure and 2 points for a previous stroke or transient ischemic attack. The study patients were divided into 3 groups according to their CHADS2 scores: group 1, score 0; group 2, score 1–2; and group 3, score 3–6. These cutoff values were determined according to a previous study on the risk of stroke [15]. Group 1 (low risk), group 2 (intermediate risk), and group 3 (high risk) included 154, 416, and 154 patients, respectively.

Intervention strategies

A diseased vessel was defined as a major epicardial artery with ≥50% stenosis. Revascularization was recommended for all patients with ≥70% diameter obstruction in any artery supplying a significant proportion of the myocardium. Percutaneous coronary intervention was recommended if there were 1 or 2 target lesions; meanwhile, coronary artery bypass grafting (CABG) was preferred in patients with 3-vessel or left main coronary artery disease (CAD).

Clinical follow-up for endpoint

All patients were kept in the CCU for at least 5 days. During their stay at the CCU, all study subjects were followed up with continuous ECG monitoring for the occurrence of AF, which was defined as an irregular narrow complex rhythm with the absence of discrete P waves. The study endpoint was an episode of new-onset AF that lasted more than 30 seconds during hospitalization at the CCU.

Statistical analysis

Data are expressed as mean ± standard deviation for numeric variables and numbers (percent) for categorical variables. Comparisons of continuous variables between groups were performed by Student’s t-test or one-way ANOVA test. Subgroup comparisons of categorical variables were assessed by the χ2 test or Fisher’s exact test. Univariate analysis was performed for analyzing the relationships between new-onset AF and clinical factors including statin use and CHADS2 score. Variables significantly associated with the presence of new-onset AF were entered into a multivariate regression model. Multivariate logistic regression analysis was performed to determine the independent predictors of new-onset AF. All data analyses were performed with SPSS software (version 17; SPSS, Chicago, IL, USA). The level of statistical significance was set at P < 0.05.

Results

Patient characteristics

A total of 724 consecutive patients (582 men, 80%) were enrolled in this study. The mean age in our cohort was 67 ± 12 years. Seventy-eight (10.8%) developed new-onset AF, and 273 (37.7%) were on a statin at the time of admission. The mean age in our cohort was 67 ± 12 years. Seventy-eight (10.8%) developed new-onset AF, and 273 (37.7%) were on a statin at the time of admission. The baseline characteristics of all patients are shown in Table 1. Among the subjects, 64.1% had hypertension, 36.6% had diabetes mellitus, 18.4% had renal insufficiency, 12.2% had previous stroke/transient ischemic attack, and 5.9% had previous heart failure. The CHADS2 scores of groups 1, 2, and 3 were 0, 1.46 ± 0.50, and 3.57 ± 0.70, respectively. Patients with high CHADS2 scores tended to be older and had increased left atrial (LA) diameter, lower left ventricular ejection fraction (LVEF), higher Killip classification, elevated C-reactive protein (CRP) level, and a higher frequency of underlying
Table 1. Baseline characteristics of patients according to CHADS<sub>2</sub> scores.

|                  | CHADS<sub>0</sub> | CHADS<sub>1–2</sub> | CHADS<sub>≥3</sub> | P     |
|------------------|------------------|-------------------|------------------|-------|
| Age (years)      |                 |                   |                  | <0.001|
| (n = 154)        | (n = 416)       | (n = 154)         |                  |       |
| 59.3 ± 11.1      | 67.1 ± 11.8     | 75.6 ± 7.7        |                  |       |
| Male             | 140 (90.9)      | 336 (80.8)        | 106 (68.8)       | <0.001|
| Hypertension     | 0 (0.0)         | 316 (76.0)        | 148 (96.1)       | <0.001|
| Diabetes mellitus| 0 (0.0)         | 159 (38.2)        | 106 (68.8)       | <0.001|
| Renal insufficiency| 10 (6.5)    | 76 (18.3)         | 47 (30.5)        | <0.001|
| Previous PCI     | 8 (5.2)         | 45 (10.8)         | 23 (14.9)        | 0.019 |
| Previous CAGB    | 3 (1.9)         | 18 (4.3)          | 10 (6.5)         | 0.143 |
| Previous MI      | 9 (5.8)         | 51 (12.3)         | 19 (12.3)        | 0.075 |
| Previous stroke/TIA| 0 (0.0)     | 4 (1.0)           | 84 (54.9)        | <0.001|
| Previous heart failure | 0 (0.0) | 13 (3.1)         | 30 (19.5)        | <0.001|
| Killip ≥ 1       |                  |                   |                  | <0.001|
| Killip > 1       | 116 (75.3)      | 237 (57.0)        | 55 (35.7)        |       |
| Medication use at index admission  |         |                   |                  |       |
| β-blocker        | 86 (55.8)       | 215 (51.7)        | 80 (51.9)        | 0.665 |
| ACE inhibitor    | 104 (67.5)      | 255 (61.3)        | 73 (47.4)        | 0.001 |
| Calcium channel blocker| 6 (3.9) | 120 (28.8)       | 70 (45.5)        | <0.001|
| Statin           | 66 (42.9)       | 164 (39.4)        | 43 (27.9)        | 0.014 |
| CRP (mg/dl)      | 0.83 ± 1.28     | 0.95 ± 1.51       | 1.33 ± 1.80      | 0.027 |
| CHADS<sub>2</sub>score | 0            | 1.47 ± 0.50       | 3.57 ± 0.70      | <0.001|

Values are mean ± SD or number (%). MI: myocardial infarction; PCI: percutaneous coronary intervention; CAGB: coronary artery bypass grafting; TIA: transient ischemic attack; LVEF: left ventricular ejection fraction; ACE: angiotensin-converting enzyme; A II: angiotensin II; CRP: C-reactive protein.

Factors associated with new-onset AF

Patients with new-onset AF tended to be older, have increased LA diameter, have lower LVEF, have higher Killip classification, have elevated CRP level, and were more likely to have a higher CHADS<sub>2</sub> score than patients without new-onset AF (all P < 0.05) (Table 2). In addition, new-onset AF occurred less frequently among statin users compared with nonusers (P < 0.001). Other demographic variables were similar between the groups.

Table 3 lists the angiographic characteristics and interventional strategies of patients with and without new-onset AF. Coronary angiography was performed in 566 patients: 64 (82%) in the AF group and 502 (78%) in the non-AF group. Among patients with new-onset AF, insignificant CAD was found in 3 patients (4.7%), single-vessel disease in 5 (7.8%), and multi-vessel disease in 56 (87.5%). Patients with new-onset AF had significantly more CAD than those without new-onset AF (P < 0.001). Revascularization procedures were performed in 462 patients: 54 (69%) in the AF group and 408 (63%) in the non-AF group. The technique applied, either percutaneous or surgical, differed significantly between the two groups. Patients with new-onset AF underwent CABG more frequently than those without new-onset AF (48.1% vs. 11.0%, P < 0.001).

Independent predictors of new-onset AF

In order to investigate the independent predictors of new-onset AF in AMI patients, multivariate logistic regression analysis was performed with the following factors: CHADS<sub>2</sub> score (i.e., congestive heart failure, hypertension, age >75 years, diabetes mellitus, and prior stroke or transient ischemic attack); serum levels of CRP; LA diameter; LVEF; Killip classification; extent of CAD; in-hospital CAGB; and medications (i.e., ACE inhibitors, β-blockers, and statins). The use of statins (odds ratio [OR], 0.22; 95% CI, 0.06–0.85), LA diameter (OR, 1.08; 95% CI, 1.00–1.17), CHADS<sub>2</sub> score (OR, 1.53; 95% CI, 1.02–2.26), and in-hospital CAGB (OR, 4.42; 95% CI, 1.39–14.04) were independent predictors of new-onset AF in patients presenting with AMI (Table 4).

Relationship between CHADS<sub>2</sub> score and effect of statins on new-onset AF

In the overall cohort, statin use was associated with a lower risk of developing new-onset AF. In patients with CHADS<sub>2</sub> scores of 0, the incidence of new-onset AF was significantly lower in the statin group than in the non-statin group (1.5% vs. 9.1%, P = 0.047) (Figure 2). Patients with CHADS<sub>2</sub> scores of 1 or 2 also had a significantly lower risk of developing new-onset AF if they were taking statins (4.9% vs. 15.5%, P = 0.001). However, the benefit of statin use on the development of new-onset AF was not evident in patients with CHADS<sub>2</sub> scores ≥3. Moreover, patients with CHADS<sub>2</sub> scores ≤2 had significantly reduced CRP level if they were taking statins (P < 0.05) (Figure 3). The effect of statin therapy on CRP level was limited in patients with CHADS<sub>2</sub> scores ≥3. Multivariate logistic regression analysis confirmed the benefit of statin use on new-onset AF in patients with CHADS<sub>2</sub> scores ≤2 (OR, 0.34; 95% CI, 0.14–0.81).

Discussion

The present results indicate that in a cohort of AMI patients, the incidence of new-onset AF was increased in patients with higher CHADS<sub>2</sub> scores. Statin use was associated with a lower risk of developing new-onset AF. The effect of statin therapy on CRP level and new-onset AF was evident in patients with CHADS<sub>2</sub> scores ≤2 but not in patients with high CHADS<sub>2</sub> scores. These findings suggest that the CHADS<sub>2</sub> score may help identify the AMI patients who will benefit most from statin use for the prevention of new-onset AF.

Some clinical observational and experimental studies suggest that the use of statins protects against AF. Additionally, a recent meta-analysis of 6 randomized controlled trials (3,557 patients) suggests that the use of statins is significantly associated with a decreased risk of the incidence or recurrence of AF in patients with sinus rhythm with a history.
of previous AF, undergoing cardiac surgery, or after ACS [16]. Our data are consistent with those in literature and demonstrate that statin treatment is associated with a lower incidence of new-onset AF in patients with AMI. There are various possible mechanisms of the antiarrhythmic effects of statins against AF. Accumulating evidence suggests that both inflammation and oxidative stress are involved in the development, recurrence, and persistence of AF [17,18]. These conditions are associated with enhanced myocardial tissue inflammation and atrial remodeling, which might serve as a substrate for the development of AF [19]. Moreover, elevated CRP levels are related to future AF development, AF persistence, and recurrence after cardioversion [20]. The capacity of statins to reduce inflammation, CRP levels, and oxidative stress is well-established [21–23]. This may explain the potential beneficial effect of statins against AF. Finally, statins may protect against AF in postoperative patients by modulating the autonomic nervous system against enhanced postoperative sympathetic activity [24], which increases susceptibility to AF. This could represent an alternative antiarrhythmic mechanism of statins against AF in such patients.

The CHADS² score, which was initially developed for stroke risk stratification in AF patients, is a convenient scoring system for evaluating the complexity of comorbidities in patients. Previous study demonstrates that CHADS² score is useful to predict CRP levels, LA thrombus formation, and prognosis in patients with nonrheumatic AF [25]. In the current study, we also showed that patients with high CHADS² scores had elevated CRP levels and a higher frequency of underlying disease. The components of the CHADS² score, including heart failure, hypertension, old age, and diabetes, are associated with an increased risk of the development of AF [11]. A recent study shows that high CHADS² scores are associated with advanced atrial remodeling including structural (i.e., enlarged LA size) and electrophysiological (i.e., low LA voltage and prolonged activation time) changes, which result in recurrence after AF ablation [14]. In addition, the CHADS²

Figure 1. Incidence of new-onset AF in AMI patients according to CHADS² score. AF, atrial fibrillation; AMI, acute myocardial infarction.
doi: 10.1371/journal.pone.0074709.g001
strategies of patients with and without AF.

Table 2. Baseline characteristics of patients with and without AF during hospitalization.

|                | With AF  | Without AF | P    |
|----------------|----------|------------|------|
| (n = 78)       | (n = 646)          |
| Age (years)    | 71.7 ± 10.0 | 66.7 ± 12.2 | 0.001|
| Male           | 66 (86.6)  | 516 (79.9)  | 0.319|
| Hypertension   | 54 (69.2)  | 410 (63.5)  | 0.316|
| Diabetes mellitus | 31 (38.7) | 234 (36.2)  | 0.542|
| Renal insufficiency | 16 (20.5) | 117 (18.1)  | 0.605|
| Previous PCI   | 13 (16.7)  | 63 (9.8)    | 0.080|
| Previous CABG  | 5 (6.4)    | 26 (4.0)    | 0.367|
| Previous MI    | 13 (16.7)  | 66 (10.2)   | 0.084|
| Previous stroke/TIA | 14 (17.9) | 74 (11.5)   | 0.098|
| Previous heart failure | 7 (9.0)   | 36 (5.6)    | 0.211|
| Left atrial diameter (mm) | 42.7 ± 8.3 | 39.3 ± 6.0  | 0.014|
| LVEF (%)       | 38.6 ± 15.2| 44.6 ± 13.4 | 0.004|
| Killip classification | <0.001  |            |      |
| Killip = 1     | 27 (34.6)  | 380 (58.9)  |      |
| Killip > 1     | 51 (65.4)  | 265 (41.1)  |      |
| Medication use at index admission |            |            |      |
| β-blocker      | 33 (42.3)  | 348 (53.9)  | 0.053|
| ACE inhibitor  | 31 (39.7)  | 401 (62.1)  | <0.001|
| Calcium channel blocker | 17 (21.8) | 179 (27.7)  | 0.267|
| Statin         | 12 (15.4)  | 261 (40.4)  | <0.001|
| CRP (mg/dl)    | 1.52 ± 2.16 | 0.94 ± 1.42 | 0.043|
| CHADS2 score   | 2.05 ± 1.38| 1.61 ± 1.26 | 0.004|

Values are mean ± SD or number (%).
ML: myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; TIA: transient ischemic attack; LVEF: left ventricular ejection fraction; ACE: angiotensin-converting enzyme; A II: angiotensin II; CRP: C-reactive protein

Table 3. Angiographic characteristics and revascularization strategies of patients with and without AF.

|                | With AF  | Without AF | P    |
|----------------|----------|------------|------|
| (n = 78)       | (n = 646)          |
| Coronary angiography | 64        | 502        | <0.001|
| Insignificant   | 3 (4.7)   | 26 (5.2)   |      |
| Single-vessel   | 5 (7.8)   | 159 (31.7) |      |
| Multi-vessel    | 56 (87.5) | 317 (63.1) |      |
| In-hospital revascularization | 54        | 408        | <0.001|
| PCI             | 28 (51.9) | 363 (89.0) |      |
| CABG            | 26 (48.1) | 45 (11.0)  |      |

Values are mean ± SD or number (%).
P CI: percutaneous coronary intervention; CABG: coronary artery bypass grafting

Table 4. Significant multivariate predictors of new-onset atrial fibrillation.

|                | Odds ratio | 95% CI      | P    |
|----------------|------------|-------------|------|
| Statin use     | 0.223      | 0.059–0.489 | 0.028|
| Left atrial diameter (mm) | 1.084     | 1.004–1.169 | 0.039|
| CHADS2 score   | 1.528      | 1.023–2.282 | 0.038|
| In-hospital CABG | 4.422     | 1.393–14.04 | 0.012|

* Adjusted for CHADS2 score (i.e., congestive heart failure, hypertension, age > 75 years, diabetes mellitus, and prior stroke or transient ischemic attack); serum levels of C-reactive protein; left atrial diameter; left ventricular ejection fraction; Killip class; in-hospital CABG; extent of coronary artery disease; and medications (i.e., ACE inhibitors, β-blockers, and statins).

CHADS2 score in patients hospitalized for AMI, the CHADS2 score has several desirable characteristics for application in AMI patients because it is easily calculated at the bedside and includes clinical data routinely available in the CCU. The present results showed that the incidence of new-onset AF was significantly increased in AMI patients with higher CHADS2 scores: 5.8%, 11.3%, and 14.3% in groups 1, 2, and 3, respectively.

Furthermore, our results demonstrated that the CHADS2 score may help in identifying AMI patients who will benefit most from statin use for the prevention of new-onset AF. Among individuals presenting with AMI, those with CHADS2 scores ≤2 had a significantly lower risk of developing AF if they were taking statins (OR, 0.34; 95% CI, 0.14–0.81). However, patients with CHADS2 scores ≥3 did not exhibit similar benefits from statin therapy. Although the mechanism through which the CHADS2 score modifies the effect of statins on new-onset AF in AMI patients is unclear, high CHADS2 scores may be linked to a great burden of systemic inflammation that may attenuate the beneficial effect of statins against the development of AF. Indeed, our data showed that patients with CHADS2 scores ≥2 had significantly reduced CRP level if they were taking statins. However, the effect of statin therapy on CRP level was limited in patients with CHADS2 scores ≥3. Further prospective and large-scale trials are required to determine whether the aggressive treatment of the underlying disease decreases the incidence of new-onset AF in AMI patients with high CHADS2 scores.

Study limitations

This study has some limitations that should be considered. First, the present study included a small population at a single center. The present findings should be confirmed in a large multicenter trial. Second, we only followed the patients during their stay at the CCU. New-onset AF occurring beyond this period will be missed. Third, although we were unable to determine how the CHADS2 score affects the relationship between statin therapy and the risk of developing AF, the mechanisms described above may partly explain the inverse correlation between the CHADS2 scores and effectiveness of statin use on new-onset AF in patients with AMI. Further
studies are needed to clarify the exact interaction between statins and AF.

**Conclusions**

New-onset AF is a common complication of AMI. Statin use is associated with a lower risk of developing AF in AMI patients. The CHADS\textsubscript{2} score is a convenient scoring system for predicting the incidence of AF and may help in identifying the patients who will benefit most from statins for the prevention of arrhythmia after AMI.
Figure 3. Relationship between CHADS$_2$ score and the effect of statin therapy on CRP level in patients with AMI. CRP, C-reactive protein.

doi: 10.1371/journal.pone.0074709.g003
Author Contributions

Conceived and designed the experiments: S-SH W-LC. Performed the experiments: H-BL P-HH. Analyzed the data: S-10.

References

1. Goldberg RJ, Zarzabki J, Lessard D, Wu J, Gore JM (2002) Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: A community-wide perspective. Am Heart J 143: 519–527. doi:10.1067/mhj.2002.120410. PubMed: 11868060.

2. Rathore SS, Berger AK, Weinfturt KP, Schulman KA, Oetgen WJ et al. (2000) Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. Circulation 101: 969–974. doi: 10.1161/01.CIR.101.9.969. PubMed: 10704162.

3. Mehta RH, Dabbous OH, Granger CB, Kuznetsova P, Kline-Rogers EM et al. (2003) Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. Am J Cardiol 92: 1031–1036.

4. Schmitt J, Duray G, Gersh BJ, Hohnloser SH (2000) Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 30: 1036–1046. doi:10.1093/eurheartj/ehn579. PubMed: 19109347.

5. Shiroshita-Takeshita A, Brundel BJ, Nattel S (2005) Atrial fibrillation: basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol 13: 181–193. doi:10.1007/s10840-005-2362-y. PubMed: 16177845.

6. Page RL, Roden DM (2005) Drug therapy for atrial fibrillation: where do we go from here? Nat Rev Drug Discov 4: 899–910. doi:10.1038/nrd1876. PubMed: 16264433.

7. Murray KT, Maca MC, Yang Z (2007) Nonantiarrrhythmic drug therapy for atrial fibrillation. Heart Rhythm 4: S88–S90. doi:10.1542/hrt.511.

8. Ray KK, Cannon CP, Ganz P (2006) Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials? Am J Cardiol 98: S18–S25. doi:10.1016/j.amjcard.2006.09.034. PubMed: 17126675.

9. Almuti K, Kimawi R, Spevack D, Ostfeld RJ (2006) Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol 109: 7–15. doi:10.1016/j.ijcard.2005.05.056. PubMed: 16054715.

10. Ozaydin M, Turker Y, Erdogan D, Karabacak M, Dogan A et al. (2010) The association between statin use and development of atrial fibrillation in patients presenting with acute coronary syndrome. Int J Cardiol 141: 147–150. doi:10.1016/j.ijcard.2009.11.172. PubMed: 19106009.

11. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE et al. (2011) 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123: 104–123.

12. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW et al. (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285: 2864–2870. doi:10.1001/jama.285.22.2864. PubMed: 11401607.

13. Chao TF, Ambrose K, Tsao HM, Lin YJ, Chang SL et al. (2012) Relationship between the CHADS2 score and risk of very late recurrences after catheter ablation of paroxysmal atrial fibrillation. Heart Rhythm 9: 1185–1191. doi:10.1016/j.hrthm.2012.03.007. PubMed: 22406145.

14. Liu T, TF, Cheng CC, Lin WS, Tsoa HM, Lin YJ et al. (2011) Associations among the CHADS2 score, atrial substrate properties, and outcome of catheter ablation in patients with paroxysmal atrial fibrillation. Heart Rhythm 8: 1155–1159. doi:10.1016/j.hrthm.2011.03.016. PubMed: 21402172.

15. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ et al. (2004) Selecting patients with atrial fibrillation for anticoagulation: Stroke risk stratification in patients taking aspirin. Circulation 110: 2287–2292. doi:10.1161/01.CIR.0000145172.55640.93. PubMed: 15477396.

16. Fauchier L, Pierre B, de Labriolte A, Grimmer C, Zannad N et al. (2008) Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 51: 828–835. doi:10.1016/j.jacc.2007.09.063. PubMed: 18294568.

17. Engelmann MDM, Svendsen JH (2005) Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 26: 2083–2092. doi:10.1093/eurheartj/ehi350. PubMed: 15975993.

18. Korantzopoulos P, Koletis TM, Galaris D, Goudevenos JA (2007) The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 115: 143–153. doi:10.1016/j.ijcard.2006.04.026. PubMed: 16764958.

19. Korantzopoulos P, Koletis T, Siogas K, Goudevenos J (2003) Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med Sci Monit 9: RA225–RA229. PubMed: 12960937.

20. Liu T, Li G, Li L, Korantzopoulos P (2007) Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: A meta-analysis. J Am Coll Cardiol 49: 1642–1648. doi:10.1016/j.jacc.2006.12.042. PubMed: 17433956.

21. Luedtege TE, Vanhoren H, Tikkanen MJ (1999) Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 353: 118–119. doi:10.1016/S0140-6736(99)67154-7. PubMed: 10023901.

22. Piengo JK, Hernandez TL, Weil KM, Poinier P, Grunwald GK et al. (2002) Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction. Circulation 106: 1447–1452. doi:10.1161/01.CIR.0000029743.68247.31. PubMed: 12234946.

23. Rosenson RS (2004) Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 173: 1–12. doi:10.1016/S0021-9150(03)00239-9. PubMed: 15177118.

24. Liu T, Li GP (2006) Statins may prevent postoperative atrial fibrillation through autonomic modulation. Am J Cardiol 97: 1266. doi:10.1016/j.amjcard.2005.11.016. PubMed: 16910309.

25. Maehama T, Okura H, Imai K, Yamada R, Obase K et al. (2010) Usefulness of CHADS2 score to predict C-reactive protein, left atrial blood stasis, and prognosis in patients with nonrheumatic atrial fibrillation. Am J Cardiol 106: 535–538. doi:10.1016/j.amjcard.2010.03.067. PubMed: 20691312.

26. Chao TF, Liu CJ, Chen SJ, Wang KL, Lin YJ et al. (2012) CHADS2 score and risk of new-onset atrial fibrillation: A nationwide cohort study in Taiwan. Int J Cardiol [Epub ahead of print]. PubMed: 23290330.

CHADS2 Score and Effect of Statin on New-Onset AF SH. Contributed reagents/materials.analysis tools: J-WC S-JL. Wrote the manuscript: S-SH.